Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
CureVac (CVAC)
NASDAQ:CVAC
Holding CVAC?
Track your performance easily
Earnings Data
Report Date
Apr 23, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
―Last Year’s EPS
―Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 12, 2024
|% Change Since: 2.87%
|Next Earnings Date:Apr 23, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a strong positive trajectory for CureVac, with significant licensing deals, promising pipeline developments, and strategic cost reductions. However, ongoing litigation and certain financial impairments present challenges.Company Guidance
During the third quarter of 2024, CureVac reported significant financial and strategic achievements. The company secured a new licensing agreement with GSK valued at up to EUR 1.45 billion, which included an upfront payment of EUR 400 million fully booked in Q3, bolstering their cash position to EUR 550.9 million. This financial strength supports CureVac's strategic transformation, including a 30% workforce reduction by year-end 2024 aimed at reducing operational expenses by over 30% starting in 2025. CureVac is advancing its pipeline with promising developments in oncology and infectious diseases, including a new cancer vaccine for squamous non-small cell lung cancer and a UTI vaccine program targeting uropathogenic E. coli. The company plans to leverage these advances, along with strong partnerships and a robust IP portfolio, to maintain a solid financial runway into 2028, positioning itself for continued growth and innovation.New Licensing Agreement with GSK
CureVac announced a licensing agreement with GSK valued up to EUR 1.45 billion, including an upfront payment of EUR 400 million fully booked in Q3 2024.
Promising Glioblastoma Phase I Study Data
Preliminary data from the Phase I study in glioblastoma showed promising immunogenic responses, with 77% of patients showing CD8 T-cell responses.
Strong Cash Position and Financial Outlook
CureVac reported a strong cash position of EUR 550.9 million as of Q3 2024, with a cash runway extending into 2028.
Operational Cost Reduction Initiatives
Initiatives such as a 30% workforce reduction are expected to reduce operational expenses by over 30% starting in 2025.
Pipeline Expansion
Expansion in both oncology and infectious diseases, including a new program for urinary tract infections and a cancer vaccine targeting lung cancer.
---
CVAC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CVAC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $2.79 | $2.88 | +3.23% |
| Aug 15, 2024 | $3.31 | $3.25 | -1.81% |
| May 23, 2024 | $3.91 | $3.97 | +1.53% |
| Apr 24, 2024 | $2.60 | $2.51 | -3.46% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does CureVac (CVAC) report earnings?
CureVac (CVAC) is schdueled to report earning on Apr 23, 2025, TBA Not Confirmed.
What is CureVac (CVAC) earnings time?
CureVac (CVAC) earnings time is at Apr 23, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CVAC EPS forecast?
Currently, no data Available
---